JSTOR is a not-for-profit service that helps scholars, researchers, and students discover, use, and build upon a wide range of content in a trusted digital archive. We use information technology and tools to increase productivity and facilitate new forms of scholarship. For more information about JSTOR, please contact support@jstor.org. 
In the past decade, nosocomial infections caused by yeast have increased significantly. In the United States, yeast infections rank as the fourth most common cause of nosocomial bloodstream infection. 1, 2 The prevalence of nosocomial candidemia increased 27-fold from 1981 through 1993 at a hospital in Taiwan. 3, 4 The dramatic increases in the prevalence of fungal infections are probably the result of alterations in immune status associated with the acquired immunodeficiency syndrome epidemic, cancer chemotherapy, organ and bone marrow transplantation, 5 frequent broad-spectrum antibacterial therapy, and invasive hospital procedures.
Currently available antifungal drugs can have troublesome side effects, are ineffective against some fungi, and lead to the development of resistance. Antifungal drug resistance has become an important issue for a variety of fungal infections. Oropharyngeal candidiasis due to drug-resistant fungi is a major problem for patients infected with human immunodeficiency virus. 6 One-third of patients with late-stage acquired immunodeficiency syndrome had drug-resistant strains of Candida albicans in their mouth in one report. 7 The rate of invasive fungal infection among liver transplant patients in another study was 11% and 40% of the patients with systemic fungal infection died. Seventy-two percent of these deaths were attributed to the fungal infection. 8 Candida species have varying degrees of susceptibility to common antifungal agents. C. lusitaniae is relatively resistant to amphotericin B.
9 C. krusei and C. glabrata are less susceptible to fluconazole than are other Candida species. [10] [11] [12] Although C. tropicalis is less commonly isolated from clinical specimens than is C. albicans, it is one of the most common non-albicans Candida species 13, 14 and it is always associated with diseases. 15, 16 Among non-albicans Candida species, C. tropicalis is considerably clinically important because it develops fluconazole resistance rapid-ly 17 and the rate of resistance to fluconazole of clinical C. tropicalis isolates is increasing. [18] [19] [20] [21] We previously reported a national survey in Taiwan in which 22 hospitals contributed 660 clinical yeast isolates. 22 The current study showed that the levels of susceptibility to fluconazole of Candida species were different among different species and also among the same species from different sources. Our data suggested that, in addition to C. krusei and C. glabrata, C. tropicalis should be on the list of yeast for which fluconazole resistance is common.
METHODS

Organisms and Medium
Yeast isolates were collected from 22 hospitals participating in Taiwan Sur veillance of Antimicrobial Resistance of Yeasts (TSARY). Six were tertiar y-care medical centers, 14 were regional hospitals, and 2 were local hospitals. Each hospital was asked to submit up to 10 C. albicans and 40 non-albicans Candida species during the collection period, from April 15 to June 15, 1999. One isolate was accepted from each episode of infection. Isolates were stored frozen at -70°C in bead-containing Microbank cr yovials (PRO-LAB Diagnostics, Austin, TX). At the end of the collection period, isolates were kept frozen and transported to the National Health Research Institutes laborator y within 24 hours. The isolates were first subcultured on Sabouraud dextrose agar (BBL Becton Dickinson, Cockeysville, MD) to check for purity and identification. Pure isolates were labeled and stored in vials containing 50% glycerol at -70°C for further analysis.
Antifungal Susceptibility Testing
The minimum inhibitory concentration (MIC) to amphotericin B or fluconazole of each yeast was determined by in vitro antifungal susceptibility testing according to guidelines published by the National Committee for Clinical Laboratory Standards. 23 The powder of RPMI medium 1640 was provided by Gibco BRL (Cat.# 31800- Isolates with a MIC of 2 µg/mL or greater were considered to be resistant to amphotericin B. Isolates with a MIC of 1 µg/mL or less were considered to be susceptible. Isolates with a MIC of 64 µg/mL or more were considered to be resistant to fluconazole. Isolates with a MIC of 8 µg/mL or less were considered to be susceptible. Isolates with a MIC between 16 and 32 µg/mL were susceptible-dose dependent. The MICs of 50% and 90% of the total population were defined as MIC 50 and MIC 90 , respectively.
Database and Analysis
In addition to identifying isolates, contributing hospitals also provided the following information about each isolate: location and type of hospital, genus and species as identified by each hospital, source (urine, sputum, blood, wound, and 48 other sources), and procedures for identification. An analysis was performed using Epi-Info software (version 6.04; Centers for Disease Control and Prevention, Atlanta, GA). 24 The significance of differences in proportions was determined by the chi-square test with Yate's correction.
RESULTS
Candida Species From Different Sources
A total of 632 isolates were analyzed for their susceptibilities to amphotericin B and fluconazole. C. albicans was the most common species (37.5% of all isolates). C. tropicalis (25.8%) and C. glabrata (24.7%) were the two most common non-albicans Candida species followed by C. parapsilosis (8.1%), C. krusei (1.6%), and others (2.3%). When classified according to the sources, 273 (43.2%) of the isolates were from urine, 152 (24.1%) were from sputum, 51 (8.1%) were from blood, 49 (7.8%) were from wounds, and 107 (16.8%) were from other sites. 
Susceptibilities to Amphotericin B and Fluconazole
The susceptibilities to amphotericin B are listed in Table 1 . Only 3 of 632 isolates, one each of C. famata, C. krusei, and C. tropicalis, were resistant to amphotericin B. The MICs ranged from 0.06 to 2 µg/mL. The MIC 50 of these isolates was 0.5 µg/mL and the MIC 90 was 1 µg/mL. C. krusei were less susceptible to amphotericin B than were the other species, with MICs ranging from 0.5 to 2 µg/mL, a MIC 50 of 1 µg/mL, and a MIC 90 of 2 µg/mL.
The susceptibilities to fluconazole are listed in Table 2 . A total of 53 (8.4%) and 45 (7.1%) isolates were resistant and susceptible-dose dependent. The MIC 50 of these isolates was 1 µg/mL and the MIC 90 was 16 µg/mL. C. krusei (70%), C. tropicalis (15%), and C. glabrata (8%) isolates had higher rates of resistance to fluconazole than did C. albicans (4%) and other Candida species (0%). No C. krusei isolate was susceptible to fluconazole and the MIC 50 of this species was 64 µg/mL. Approximately 78% and 79% of C. glabrata and C. tropicalis isolates, respectively, were susceptible to fluconazole. No C. parapsilosis isolate was resistant to fluconazole. Non-albicans Candida species had higher rates of resistance to fluconazole than did C. albicans (44 of 395 [11.2%] vs 9 of 237 [3.8%]; P = .002). Isolates from hospitals affiliated with tertiary-care medical centers had a higher rate of resistance to fluconazole than did those from regional and local hospitals (25 of 219 [11.4%] vs 27 of 410 [6.6%]; P = .05).
Species and Sources Accounting for Susceptibilities to Fluconazole
Candida species isolated from different sources had different susceptibilities to fluconazole (Table 3 ). All isolates from blood, with the exception of 4 C. tropicalis isolates and 1 C. krusei isolate, were susceptible to fluconazole (Table 3) . Candida species isolated from different sources had different MICs (MIC 50 and MIC 90 ) to fluconazole ( Table 4 ). The MIC 50 of isolates from urine (4 µg/mL) was higher than that of isolates from other sources (0.5 to 1 µg/mL). The MIC 90 of isolates from wounds (8 µg/mL) was lower than that of isolates from blood, sputum, and urine (16 to 32 µg/mL).
Co-resistance to Both Amphotericin B and Fluconazole
The trend of co-resistance to amphotericin B and fluconazole is outlined in Table 5 . Fewer isolates with MICs to amphotericin B of 0.5 µg/mL or less were resistant to fluconazole compared with isolates with higher MICs (1 µg/mL or greater) to amphotericin B (30 of 462 vs 23 of 170; P = .007). Isolates with lower MICs to amphotericin B (0.5 µg/mL or less) had lower MIC 50 and MIC 90 to fluconazole than did isolates with higher MICs (1 µg/mL or greater) to amphotericin B (1 vs 2 µg/mL and 16 vs 64 µg/mL, respectively).
DISCUSSION
According to in vitro antifungal susceptibility testing, 0.5% and 8.4% of isolates were considered to be resistant to amphotericin B and fluconazole, respectively. The difference in rate of resistance between fluconazole and amphotericin B is a result of different mechanisms of antifungal activity, 6, 25 frequency of use, different molecular mechanisms of drug resistance, 5, 26 or all three. Two of three isolates resistant to amphotericin B (one C. krusei and one C. tropicalis) were also resistant to fluconazole. Although the rate of resistance to amphotericin B was low, there was a trend of co-resistance to amphotericin B and fluconazole.
Fungal infections caused by non-albicans Candida species have been increasing dramatically.
27-29 C. krusei and C. glabrata have been considered intrinsically more resistant to fluconazole. 10, 11 In this study, no C. krusei isolate was susceptible to fluconazole, but C. glabrata was less resistant to fluconazole than in other studies (8% vs 13% or 45.4%). 19, 30 Overall, non-albicans Candida species had higher rates of resistance to fluconazole than did C. albicans. Most of the Candida species isolates from blood 17, 31 These findings may explain why C. tropicalis (15%) had a higher rate of resistance to fluconazole than did C. albicans (4%) and C. glabrata (8%).
Isolates of the same species from different sources showed different susceptibilities to fluconazole. For example, C. glabrata isolates from sputum had a higher rate of resistance (15%) to fluconazole than did those from blood (0%) or urine (7.5%), whereas C. tropicalis isolates from blood had a higher rate of resistance (33.3%) to fluconazole than did those from sputum (13.9%) or urine (17.8%). The fact that isolates from tertiary-care medical centers had higher rates of resistance to fluconazole than did those from regional and local hospitals needs to be investigated further.
Different levels of susceptibility to fluconazole in the same species from different sources complicates diagnosis and treatment in the clinical setting. Hence, accurate identification to the species level and susceptibility testing are crucial for clinical management, especially for the emerging non-albicans Candida species that are resistant to fluconazole.
